← ANALYST RATINGS · TIPRANKS
GRAIL Inc (GRAL): analyst forecast and price target
Analyst consensus
Moderate Buy6 Buy4 Hold0 Sell
Ratings of 10 analysts in the last 3 months12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $129, the highest $180, the lowest $56.00. The average is +9.2% from the last price of $118.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $143 → $123−14.0% | Hold | +4.4% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $143 → $123−14.0% | Hold | +4.4% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $145 → $124−14.5% | Hold | +5.3% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $141 → $121−14.2% | Hold | +2.7% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $145 → $124−14.5% | Hold | +5.3% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $139 → $119−14.4% | Hold | +1.0% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| Kallum Titchmarsh★★★★★★★★★★#2647 · hits 58% · avg +9.6% | Morgan Stanley | $60.00 → $120+100.0% | Hold | +1.9% | Reiterated | 13.10.26on TipRanks 08:55 | +2.2%next day +0.6% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $88.00 → $180+104.5% | Buy | +52.8% | Reiterated | 13.10.26on TipRanks 08:41 | +2.2%next day +0.6% | ↗ |
| Evie Koslosky★★★★★★★★★★#9740 · hits 58% · avg −3.1% | Goldman Sachs | $75.00 → $120+60.0% | Hold | +1.9% | Reiterated | 05.10.26on TipRanks 07:40 | +6.9%next day −11.5% · 5 days −11.3% | ↗ |
| Doug Schenkel★★★★★★★★★★#216 · hits 65% · avg +26.2% | Wolfe Research | $105 → $175+66.7% | Buy | +48.5% | Reiterated | 02.10.26on TipRanks 09:50 | +7.3%next day +6.9% · 5 days −3.0% | ↗ |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | $75.00 → $155+106.7% | Buy | +31.6% | Reiterated | 01.10.26on TipRanks 08:35 | −5.6%next day +7.3% · 5 days −1.3% | ↗ |
| Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% | Canaccord Genuity | $80.00 → $150+87.5% | Buy | +27.3% | Reiterated | 28.09.26on TipRanks Sep 27 23:30 | +5.3%next day +3.2% · 5 days +15.0% | ↗ |
| Robert Bamberger | Robert W. Baird | $86.00 → $118+37.2% | Buy | +0.2% | Reiterated | 22.09.26on TipRanks 07:25 | +0.5%next day +0.7% · 5 days +27.0% | ↗ |
| Bradley Bowers★★★★★★★★★★#1314 · hits 90% · avg +72.1% | Mizuho Securities | — | Buy | — | Reiterated | 22.09.26on TipRanks 07:20 | +0.5%next day +0.7% · 5 days +27.0% | ↗ |
| Dan Leonard★★★★★★★★★★#656 · hits 62% · avg +14.1% | RBC Capital | $84.00 | Hold | −28.7% | Reiterated | 21.09.26on TipRanks Sep 23 21:45 | +32.1%next day +0.5% · 5 days +23.9% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $56.00 | Hold | −52.5% | Reiterated | 06.08.26on TipRanks 07:45 | −14.4%next day +9.0% · 5 days +6.4% | ↗ |
| Paige Chamberlain★★★★★★★★★★#7338 · hits 100% · avg +13.9% | Wolfe Research | — | Hold | — | Initiated | 01.06.26on TipRanks Jun 2 03:05 | −10.4%next day −7.1% · 5 days −1.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering GRAIL Inc
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $99.00 at a price of $140 (−29.3%); now: $129 at $118 (+9.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 0 | 0 | 0 | 0 | 0 |
| Buy | 7 | 7 | 8 | 6 | 13 | 15 |
| Hold | 4 | 7 | 6 | 5 | 8 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-2.50 (from $-3.22 to $-1.61). Last quarter: $-2.56.
Sales
Next quarter’s sales estimate — $44M (from $42M to $47M). Last quarter: $45M.
Best top-analyst consensus in the sector · General
About GRAIL Inc
- CEO: Joshua J. Ofman
- Employees: 910
- 1525 O’Brien Drive, Menlo Park, CA, 94025, US
- www.grail.com
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Data from the stock’s TipRanks forecast page, read 18 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗